315 related articles for article (PubMed ID: 33148949)
1. Microbiome modulation as a novel therapeutic approach in chronic kidney disease.
Sumida K; Lau WL; Kovesdy CP; Kalantar-Zadeh K; Kalantar-Zadeh K
Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):75-84. PubMed ID: 33148949
[TBL] [Abstract][Full Text] [Related]
2. Prebiotic, Probiotic, and Synbiotic Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-analysis.
McFarlane C; Ramos CI; Johnson DW; Campbell KL
J Ren Nutr; 2019 May; 29(3):209-220. PubMed ID: 30366767
[TBL] [Abstract][Full Text] [Related]
3. Gut Microbiota-Targeted Interventions in the Management of Chronic Kidney Disease.
Sumida K; Pierre JF; Yuzefpolskaya M; Colombo PC; Demmer RT; Kovesdy CP
Semin Nephrol; 2023 Mar; 43(2):151408. PubMed ID: 37619529
[TBL] [Abstract][Full Text] [Related]
4. Microbiota issue in CKD: how promising are gut-targeted approaches?
Cosola C; Rocchetti MT; Sabatino A; Fiaccadori E; Di Iorio BR; Gesualdo L
J Nephrol; 2019 Feb; 32(1):27-37. PubMed ID: 30069677
[TBL] [Abstract][Full Text] [Related]
5. Novel intestinal dialysis interventions and microbiome modulation to control uremia.
Sumida K; Lau WL; Kalantar-Zadeh K; Kovesdy CP
Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):82-91. PubMed ID: 34846313
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis.
Rukavina Mikusic NL; Kouyoumdzian NM; Choi MR
Pflugers Arch; 2020 Mar; 472(3):303-320. PubMed ID: 32064574
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Gut Microbiota in Kidney Disease: The Future in Renal Nutrition and Metabolism.
Lambert K; Rinninella E; Biruete A; Sumida K; Stanford J; Raoul P; Mele MC; Wang AY; Mafra D
J Ren Nutr; 2023 Nov; 33(6S):S30-S39. PubMed ID: 37632511
[TBL] [Abstract][Full Text] [Related]
8. The Impact of CKD on Uremic Toxins and Gut Microbiota.
Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
[TBL] [Abstract][Full Text] [Related]
9. POTENTIAL THERAPEUTIC OPTIONS TARGETING THE GUT DYSBIOSIS IN CHRONIC KIDNEY DISEASE.
Dobrek Ł
Wiad Lek; 2022; 75(7):1757-1764. PubMed ID: 35962694
[TBL] [Abstract][Full Text] [Related]
10. Chronic Kidney Disease and Gut Microbiota: What Is Their Connection in Early Life?
Hsu CN; Tain YL
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409313
[TBL] [Abstract][Full Text] [Related]
11. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
[TBL] [Abstract][Full Text] [Related]
12. Microbiome modulation to correct uremic toxins and to preserve kidney functions.
Caggiano G; Cosola C; Di Leo V; Gesualdo M; Gesualdo L
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):49-56. PubMed ID: 31725010
[TBL] [Abstract][Full Text] [Related]
13. A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota.
Yurtdaş G; Akdevelioğlu Y
J Am Coll Nutr; 2020; 39(4):371-382. PubMed ID: 31513473
[TBL] [Abstract][Full Text] [Related]
14. Microbiota and prebiotics modulation of uremic toxin generation.
Koppe L; Fouque D
Panminerva Med; 2017 Jun; 59(2):173-187. PubMed ID: 28001024
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota in chronic kidney disease.
Cigarran Guldris S; González Parra E; Cases Amenós A
Nefrologia; 2017; 37(1):9-19. PubMed ID: 27553986
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.
Pan W; Kang Y
Int Urol Nephrol; 2018 Feb; 50(2):289-299. PubMed ID: 28849345
[TBL] [Abstract][Full Text] [Related]
17. Synbiotics Alleviate the Gut Indole Load and Dysbiosis in Chronic Kidney Disease.
Yang CY; Chen TW; Lu WL; Liang SS; Huang HD; Tseng CP; Tarng DC
Cells; 2021 Jan; 10(1):. PubMed ID: 33435396
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiome-targeted therapies for Alzheimer's disease.
Zhang T; Gao G; Kwok LY; Sun Z
Gut Microbes; 2023 Dec; 15(2):2271613. PubMed ID: 37934614
[TBL] [Abstract][Full Text] [Related]
19. An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients.
Cosola C; Rocchetti MT; di Bari I; Acquaviva PM; Maranzano V; Corciulo S; Di Ciaula A; Di Palo DM; La Forgia FM; Fontana S; De Angelis M; Portincasa P; Gesualdo L
Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34063068
[TBL] [Abstract][Full Text] [Related]
20. Understanding the gut microbiota in cancer cachexia.
Rocha IM; Fonseca DC; Torrinhas RSM; Waitzberg DL
Curr Opin Clin Nutr Metab Care; 2023 Sep; 26(5):482-489. PubMed ID: 37389459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
